In the middle of December 2018, under the leadership of Sichuan business development association, Chengdu sannuobi was invited to attend the 2018 international pharmaceutical raw materials India exhibition, and at the exhibition, the company's business profile and main products, polypeptides and other drugs were displayed in detail for 3 days.
More than 1100 companies from more than 100 countries and regions, including China, France, Germany, Italy, the United Kingdom, the United States, Japan and Singapore, participated in the exhibition, including nearly 380 companies from India.
Figure 1: sinobio's participation in CPHI India 2018
It is understood that CPHI India has attracted extensive attention from manufacturers and traders of APIs all over the world, especially in China, with the vigorous development of the pharmaceutical market in India since it was first held in 2005. Focusing on the latest products and technologies in various fields such as pharmaceutical raw materials, pharmaceutical machinery and equipment, service outsourcing and biomedicine, the exhibition is dedicated to helping the industry to find high-quality and low-cost product solutions. After more than ten years of growth and success in Mumbai, CPHI has become the largest pharmaceutical exhibition in South Asia.
Figure 2: CPHI India 2018
As a first-class professional peptide drug enterprise in China, sinobio has been closely cooperating with foreign pharmaceutical peptide manufacturers in the same industry. It not only has a cooperative relationship with Indian peptide manufacturers, but also uses its own technology to train and guide the employees of Indian factories. Shengnuo biology has also been in contact and exchange with internationally renowned peptide technology research units to study the structure and function of biotechnological drugs from multiple perspectives and in-depth, laying a solid foundation for further application in the actual accumulation of scientific data.
Sanuobio has also participated in the key technology research of peptide chemical modification and industrial scale preparation, a major new drug creation project of the 11th five year plan. The national science and technology innovation fund for small and medium-sized enterprises funded the project "new anti heart failure drug nesiritide" has entered the clinical research stage.
Cphiindia is not only conducive to the development and extension of upstream and downstream industrial chain, but also to a clearer understanding of the industry development trend, laying a foundation for more international cooperation and playing a positive and far-reaching role in shaping the image of a first-class international enterprise.
Shengnuo bio PRODUCT
Best sales manager contact
| Contacts | Roleagh |
|---|---|
| Tel | 86-28-88203630 |
| Fax | 86-28-88203630 |
| roleagh@gmail.com | |
| 2539328606 | |
| LEI LI |
About Shengnuo
Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.